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Summary
The results of the application of the 3-source Capture-Recapture method to determine
the estimated national prevalence of opiate use are summarised for Ireland as a whole,
for Dublin and for the rest of Ireland excluding Dublin for the years 2000 and 2001.
Ireland
Year Sex Age group Estimate Lower
Bound
Upper
Bound
Rate/1000
pop.
2000 M+F 15-64 14,158 12,884 15,883 5.6
2001 M+F 15-64 14,452 13,405 15,819 5.6
Dublin
Year Sex Age group Estimate Lower
Bound
Upper
Bound
Rate/1000
pop.
2000 M+F 15-64 12,268 11,204 13,725 16.1
2001 M+F 15-64 12,456 11,519 13,711 16.0
Rest of Ireland (excluding Dublin)
Year Sex Age group Estimate Lower
Bound
Upper
Bound
Rate/1000
pop.
2000 M+F 15-64 2,526 1,893 3,639 1.0
2001 M+F 15-64 2,225 1,934 2,625 0.9
Based on a report submitted to the National Advisory Committee on Drugs
(NACD).
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Ireland
A summary of the results of the 3-source Capture-recapture models for Ireland for the
years 2000 and 2001 stratified by age and sex.
(NB: Lower Bound = lower 95% Confidence Limit; Upper Bound = Upper 95% Confidence Limit)
Year Sex Age Group Estimates Lower
Bound
Upper
Bound
Rate/1000 1
2000 Males 15-24 3480 3298 3691 10.4
25-34 3935 3753 4144 13.7
35-64 2344 2013 2803 3.6
Females 15-24 1866 1664 2142 5.8
25-34 1729 1542 1983 6.1
35-64 804 614 1120 1.2
Total M+F 15-64 14158 12884 15883 5.6
2001 Males 15-24 3194 3048 3363 9.5
25-34 4376 4206 4570 14.7
35-64 2228 2042 2462 3.3
Females 15-24 1999 1750 2340 6.2
25-34 1941 1765 2178 6.6
35-64 714 594 906 1.1
Total M+F 15-64 14452 13405 15819 5.6
                                                
1 Rates for this and subsequent tables are derived from CSO population estimates: “Population and
Migration Estimates April 2002, CSO 'Bulletin', 5 September 2002”
Based on a report submitted to the National Advisory Committee on Drugs
(NACD).
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Dublin
A summary of the results of the 3-source Capture-recapture models for Dublin for the
years 2000 and 2001 stratified by age and sex.
(NB: Lower Bound = lower 95% Confidence Limit; Upper Bound = Upper 95% Confidence Limit)
Year Sex Age Group Estimates Lower
Bound
Upper Bound Rate/1000
2000 Males 15-24 3083 2915 3278 34.0
25-34 3417 3256 3607 34.3
35-64 1940 1678 2312 10.8
Females 15-24 1714 1533 1958 18.9
25-34 1497 1342 1713 14.0
35-64 617 480 857 3.2
Total M+F 15-64 12268 11204 13725 16.1
2001 Males 15-24 2735 2604 2888 30.1
25-34 3740 3589 3915 36.0
35-64 1803 1657 1992 9.9
Females 15-24 1766 1537 2085 19.4
25-34 1784 1621 2003 16.1
35-64 628 511 828 3.2
Total M+F 15-64 12456 11519 13711 16.0
Based on a report submitted to the National Advisory Committee on Drugs
(NACD).
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Rest of Ireland (excluding Dublin)
A summary of the results of the 3-source Capture-recapture models for Dublin for the
years 2000 and 2001 stratified by sex for 15-64 years combined.
(NB: Lower Bound = lower 95% Confidence Limit; Upper Bound = Upper 95% Confidence Limit)
Year Sex Age Group Estimates Lower Bound Upper Bound Rate/1000
2000 Males 15-64 1499 1266 1816 1.2
Females 15-64 1027 627 1823 0.8
Total M+F 15-64 2526 1893 3639 1.0
2001 Males 15-64 1688 1493 1940 1.3
Females 15-64 537 441 685 0.4
Total M+F 15-64 2225 1934 2625 0.9
Based on a report submitted to the National Advisory Committee on Drugs
(NACD).
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Dublin 2001 contrasted with Dublin 1996
Source for 1996 estimates: Comiskey, C., and Barry, J. (2000) A capture-recapture
study of the prevalence and implications of opiate use in Dublin, European Journal of
Public Health.
((NB: Lower Bound = lower 95% Confidence Limit; Upper Bound = Upper 95% Confidence Limit)
As the study in 1996 included individuals aged 15 to 54 years of age, the estimates for
Dublin 2001 have been recomputed to facilitate comparison.
Dublin 1996 Dublin 2001
Estimate Lower
bound
Upper
bound
Rate/1000
pop.
Estimate Lower
bound
Upper
bound
Rate/1000
pop.
M 15-24 5405 4980 5891 56 2735 2604 2888 30.1
M 25-34 3512 3276 3778 42 3740 3589 3915 36.0
M 35-54 1427 1175 1773 11 1793 1648 1980 13.0
F 15-24 1778 1525 2108 18 1766 1537 2085 19.4
F 25-34 1039 875 1265 11 1784 1621 2003 16.1
F35-54 300 206 491 2 626 509 825 4.2
Total 13461 12037 15306 21 12444 11508 13696 18.2
Note that the confidence bounds for both point estimates overlap substantially and we
conclude that there is a negligible difference in the prevalence for both years.    The
rate has declined due to the (approximately) 22%  increase in the population 15-54
years over the 5 year period.
Based on a report submitted to the National Advisory Committee on Drugs
(NACD).
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Study context
This is a report of the findings of a national 3-source capture-recapture study (CRM) 2
on the prevalence of opiate drug use in the population during the period 2000 to 2001.
The study was commissioned by the National Advisory Committee on Drugs
(NACD) following an open tendering process.  This report updates a similar Dublin-
only study for the year 1996.3  The latter study reported six prevalence estimates for
Dublin (i.e. 3 age bands for males and females).  In the present exercise, the scale of
the task was very much greater with some 56 prevalence estimates required, i.e. 3 age
bands for males and females for two years and for the following areas: the whole of
Ireland, Dublin, Rest of Ireland (excluding Dublin), ERHA and the 7 Health Boards
plus a comparison between Dublin 2001 versus 1996.
It is anticipated that the results will inform national and regional planning for service
provision by the relevant authorities.
Methods and Data
The main parameters of the study, as determined by the National Advisory Committee
on Drugs – Sub-committee on Prevalence, specified that three data sources were to be
employed in the study, namely: the Central Drug Treatment List, a national Garda
Study on Drugs, Crime and Related Criminal Activity and the Hospital In-patient
Enquiry database. Statistically valid estimates of the prevalence of opiate drug use in
the national population and by sub-region were required for the years 2000 and 2001.
In view of the sensitive nature of the data to be employed in the study, prior ethical
approval was considered essential.  A submission was made to the Ethics Committee
of the Faculty of Public Health Medicine and also to the Data Protection Commission
with suitable guarantees for the safeguarding and maintenance of data confidentiality
in the study and in all reporting of findings.  In due course, approval for the study was
                                                
2 The Capture-recapture methodology (CRM) is the principal indirect method for estimating the
prevalence of some partially hidden population such as opiate users.  While originally developed to
determine the numbers in various wildlife populations, for example, a given bird species, CRM has
gained in popularity as a useful tool to provide statistically valid estimates in epidemiological studies.
It has been extensively used in population-based opiate prevalence studies, both abroad and in Ireland,
and is recommended by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in
Lisbon.
Based on a report submitted to the National Advisory Committee on Drugs
(NACD).
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obtained from these bodies. Permission was then sought and granted to access the
Central Drug Treatment List and the Garda data. 4
In relation to HIPE, a large number of hospitals throughout the country potentially
held relevant data on attendances by individual patients with a history of opiate use.
Consequently, 44 hospital managers were written to by the NACD requesting their
co-operation and informing them that ethical approval was being sought from the
relevant hospital Ethics Committee.  Subsequently, we made individual applications
to each hospital Ethics Committee where such existed, or, as in the case of the smaller
county hospitals, to a central Ethics Committee serving several hospitals in a region.
Method
A 3-source Capture Recapture study determines a prevalence estimate based on
identifying individuals who appear in one, two or all three data sets within a given
year.  It may be helpful to visualise this in terms of the figure below (Fig. 1).  It will
be evident that individuals may be found in common between any pair of sources as
represented in the figure by T ∩ H (Treatment List and HIPE), T ∩ G (Treatment
List and Garda data), H ∩ G (HIPE and Garda data) and T ∩ H ∩ G (Treatment list,
HIPE and Garda data).  The remaining individuals are unique to each source: T
(Treatment List), H (HIPE) and G (Garda data).
Seven numbers are needed in all for the models; these are the number of individuals
common to any pair of data lists (3) and to all three data lists (1) and the numbers of
individuals who are unique to specific lists (3).  These numbers are now available to
be modelled employing a statistical technique suited to Capture-recapture modelling
and know as Log-linear analysis.  A model is selected form a variety of candidate
models and this provides an estimate of the total number (N) of individuals in our
population of drug users - this is the required prevalence estimate. The fitted model
also allows for the computation of a confidence interval (conventionally set to 95%)
associated with the prevalence estimate to give a range of values within which - with
a high degree of assurance - we believe the true prevalence value will lie.
                                                                                                                                           
3 Comiskey, C. (1998)  Estimating the prevalence of Opiate Drug Use in Dublin, Ireland.  A Report
submitted to the Department of Health & Children, Dublin.
4 One of us (AK) served on the Steering Committee for the Garda study.
Based on a report submitted to the National Advisory Committee on Drugs
(NACD).
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Figure 1 Illustration of both overlap and non-overlap of individuals common and
unique, respectively, to the three data sources.  T: Treatment List;  H: HIPE;  G:
Garda data;   T ∩ H: intersection between Treatment list and HIPE (i.e. individuals
common to both the Treatment List and HIPE); T ∩ G: intersection between
Treatment list and Garda data; H ∩ G: intersection between HIPE and Garda data;
and   T ∩ H ∩ G: intersection between all three lists.
Crucial to the success of the modelling exercise is the correct ascertainment of the 7
numbers referred to above.  Determining these numbers is by no means a trivial
matter.   In order to accomplish this, it is important to have a reasonably unambiguous
person identifier in the three data sets.  In principle, it is believed that a person’s
initials, full date of birth and sex suffices to provide a reliable match.  In practice, it
must be recognised that data recording practices can and do give rise to errors in
entering any or all of these details in routinely collected data intended for
administrative purposes.
Based on a report submitted to the National Advisory Committee on Drugs
(NACD).
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The Venn diagram below illustrates the distribution of numbers observed for 15-64
combined age band during 2001 in terms of the overlap as well as the unique cases for
the three sources. 5
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Figure 2 - An illustrative example of what the Venn diagram would look like based on
the 15- 64 combined ages and for both males and females for 2001.
Data - comparative analysis
A comparative analysis of the demographic characteristics across the data sets is of
particular interest in highlighting certain similarities and especially certain differences
in the age/sex breakdown by the three sources.  This analysis follows the removal of
duplicate records within individual data sets.  For purposes of these analyses, two
years data (2000 & 2001) have been consolidated to provide added stability in the
percentages displayed.
NB: In the following, “G” = Garda data, “H” = HIPE, “T” = Treatment List
The percentage of cases by source is as follows: Garda data (32.8%), HIPE (9.2%)
and Treatment list (57.9%).
                                                
5 These figures are for illustrative purposes only as fitting a model to the combined 15
– 64 age group would result in a poor fit due to heterogeneity.  Where numbers
permit, models are fitted to various age bands and for males and females separately as
reported below.
